SecBot SecBot
PRESS-RELEASE ·Filed Apr 6, 2026

PRAX

Praxis Precision Medicines, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This data de-risks the ongoing pivotal EMBRAVE3 trial and positions elsunersen as a best-in-class candidate for SCN2A-DEE. Traders should monitor upcoming regulatory interactions and potential fast-track expansion; consider positioning ahead of EMBRAVE3 readout. Competitive moat strengthened by PRIME and orphan designations in both US and EU.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$310.11
T+0 close · Apr 6, 2026 · via day close
Latest settled
+3.06%
T+60 · $319.60
Vs SPY
−10.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $310.11entry
  2. T+1 · 7mo ago −1.10%α −1.17% · $306.69
  3. T+5 · 7mo ago +2.22%α −1.91% · $317.00
  4. T+20 · 7mo ago +8.87%α −0.12% · $337.61
  5. T+60 · 5mo ago +3.06%α −10.41% · $319.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction (p=0.015) and meaningful functional improvements across sleep, motor function, and attention. The drug was well-tolerated with no drug-related serious adverse events, supporting its potential as a first disease-modifying therapy for this rare genetic epilepsy.

Key Facts

  • Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in SCN2A-DEE patients
  • 71% of treated patients had >50% seizure reduction; 57% had at least 28 days seizure-free
  • 100% of elsunersen patients showed functional improvements vs. none in placebo
  • No treatment-emergent or serious adverse events related to the drug
  • All nine patients continued into open-label extension with sustained benefit up to one year

Financial Impact

High-value catalyst for a rare disease with no approved therapies; potential peak sales in the hundreds of millions given orphan drug designations and precision CNS focus

market valuationpipeline valueinvestor sentiment

Risk Factors

  • Small sample size (n=9) limits statistical power despite significance
  • Pivotal EMBRAVE3 trial results may not replicate Part A efficacy
  • Regulatory path may require additional data beyond current trial design

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3268372

Track record

16 reports on PRAX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026